PRLD Prelude Therapeutics Incorporated
USHealthcareAs of 2026-07-10 16:00
Why PRLD matters now
Prelude Therapeutics Incorporated (PRLD) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.81 with -2.14% on the session and $273.6M in market capitalization; recent performance reads 1-month +1.17% and YTD +48.97%.
The latest financial table shown here is Q1 2026, with revenue of $4.6M, net income of $-10.4M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.8%.
The latest indexable market news headline is "Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes FRIEDMAN PAUL A filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.92
P/S
14.71
EV/EBITDA
-3.18
DCF Value
$3.87
FCF Yield
-17.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.7%
Operating Margin
-503.2%
Net Margin
-465.3%
ROE
-118.2%
ROA
-65.0%
ROIC
-104.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.6M | $-10.4M | $-0.13 |
| Q4 2025 | $5.6M | $-16.5M | $-0.26 |
| FY 2025 | $12.1M | $-99.5M | $-1.29 |
| Q3 2025 | $6.5M | $-19.7M | $-0.26 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.00
Target (Median)
$8.00
Target Range
$8.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.01
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.